The Tech-Broification of American Science Has Officially Begun
Trump's $5B 'Genesis Mission' bets US science leadership on AI while sidelining life sciences and credentialed expertise.
Trump's $5B 'Genesis Mission' bets US science leadership on AI while sidelining life sciences and credentialed expertise.
The White House deployed $5 billion in AI-driven research grants—framed with Manhattan Project urgency—while science adviser Michael Kratsios, lacking a formal science background, pitched Congress on a vision favoring AI, robotics, and nuclear energy over life sciences. The dual announcements signal a deliberate reordering of US research priorities away from traditional scientific institutions and toward tech-sector sensibilities, with consequences for funding, talent, and long-term public-health research.
Watch: How NIH and life-sciences institutions respond to budget repositioning as Genesis Mission criteria formalize over coming months.
Trump’s science adviser Michael Kratsios has no science background. | Image: Getty / The Verge The Trump administration unveiled the first "Genesis Mission" grants on Thursday, directing $5 billion toward hundreds of AI-driven science projects in an effort the White House has described as "comparable in urgency and ambition to the Manhattan Project." At roughly the same time, Trump's science adviser Michael Kratsios was on Capitol Hill selling lawmakers on an equally grandiose promise: " A New Golden Age " of American science, one that would prioritize artificial intelligence, robotics, and nuclear energy and downplay life sciences. Taken together, the two announcements offer the clearest picture yet of how Donald Trump wants to remak … Read the full story at The Verge.
- 01The White House deployed $5 billion in AI-driven research grants—framed with Manhattan Project urgency—while science adviser Michael Kratsios, lacking a formal science background, pitched Congress on a vision favoring AI, robotics, and nuclear energy over life sciences.
- 02The dual announcements signal a deliberate reordering of US research priorities away from traditional scientific institutions and toward tech-sector sensibilities, with consequences for funding, talent, and long-term public-health research.